BiVACOR® Receives $13 Million to Support Clinical Trials for the Company’s Total Artificial Heart
BiVACOR® , a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements.
- BiVACOR® , a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements.
- View the full release here: https://www.businesswire.com/news/home/20240220429887/en/
BiVACOR® Total Artificial Heart (TAH) in Surgeon's Hands (Photo: Business Wire)
Led by Monash University, the AHFP is comprised of a consortium of research centers in Australia in collaboration with BiVACOR. - The award will support clinical work of the BiVACOR Total Artificial Heart (TAH) and begin development for the integration of wireless power sources for the device.
- “There is a huge gap between available treatment options and the number of patients with severe heart failure.